Hyperliquid Strategies
PURR
7.48
-0.92
-10.95%
Hyperliquid Strategies
US · PURR
#2375 by market cap
Listed 1970
7.48
-0.92
-10.95%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.93, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 2 years
Margins
- Operating margin
- -47.47%
- Net margin
- 2,708.08%
Key ratios & quality
- Altman Z-Scorei
- 6.93
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2025 | 2026 |
|---|---|---|
| Revenue | 0 | 9.46M |
| Gross profit | -- | -- |
| Selling & admin expenses | 597.00K | 13.95M |
| Research & development | -- | -- |
| Operating profit | -597.00K | -4.49M |
| Pretax profit | -597.00K | 489.02M |
| Tax | 0 | 183.48M |
| Net profit | -597.00K | 305.54M |
| Basic EPS | 0 | 3 |
| Diluted EPS | 0.00 | 3.21 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|
| Revenue | -- | -- | 500.00K | 2.63M | 6.33M |
| Gross profit | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | 3.47M | 7.25M | 3.22M |
| Research & development | -- | -- | -- | -- | -- |
| Operating profit | -- | -1.21M | -2.97M | -4.62M | 3.11M |
| Pretax profit | -- | -1.21M | -286.67M | 195.18M | 593.90M |
| Tax | -- | -- | 17.80M | 42.67M | 123.01M |
| Net profit | -- | -1.21M | -304.46M | 152.51M | 470.89M |
| Basic EPS | -- | 0 | -7 | 1 | 2 |
| Diluted EPS | -- | -0.01 | -7.43 | 1.01 | 2.10 |
Balance sheet
| Line item | 2025 | 2026 |
|---|---|---|
| Total current assets | 0 | 152.41M |
| Cash & ST investments | 0 | 137.92M |
| Inventory | -- | -- |
| Total assets | 0 | 2.06B |
| Total current liabilities | 597.00K | 3.66M |
| Short-term debt | -- | -- |
| Long-term debt | -- | -- |
| Total liabilities | 597,000.00 | 187,137,000.00 |
| Total equity | -597.00K | 1.87B |
| Retained earnings | -597.00K | 304.95M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|
| Total current assets | -- | -- | 287.11M | 117.41M | 152.41M |
| Cash & ST investments | -- | -- | 281.93M | 113.06M | 137.92M |
| Inventory | -- | -- | -- | -- | -- |
| Total assets | -- | -- | 616.64M | 810.41M | 2.06B |
| Total current liabilities | 596.67K | 1.21M | 9.08M | 6.44M | 3.66M |
| Short-term debt | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- |
| Total liabilities | 596,667.00 | 1,212,921.00 | 26,874,000.00 | 66,907,000.00 | 187,137,000.00 |
| Total equity | -596.67K | -1.21M | 589.77M | 743.50M | 1.87B |
| Retained earnings | -- | -1.21M | -318.46M | -165.95M | 304.95M |
Cash flow
| Line item | 2025 | 2026 |
|---|---|---|
| Operating cash flow | 0 | -19.15M |
| Depreciation & amortization | -- | -- |
| Free cash flow | 0 | -19.15M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | 0 | 936.80M |
| Ending cash balance | 0 | 137.92M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|
| Operating cash flow | -- | 0 | -8.32M | -7.00M | -3.84M |
| Depreciation & amortization | -- | -- | -- | -- | -- |
| Free cash flow | -- | 0 | -8.32M | -7.00M | -3.84M |
| Dividends paid | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 332.00K | 645.26M |
| Ending cash balance | -- | 0 | 281.93M | 113.06M | 137.92M |
Returns & efficiency
| Line item | 2025 | 2026 |
|---|---|---|
| ROE %i | -- | 27.37 |
| ROA %i | -- | 12.44 |
| ROIC %i | -- | 27.19 |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -47.47 |
| FCF / sales %i | -- | -- |
| Current ratioi | -- | 41.62 |
| Quick ratioi | -- | 37.77 |
| Debt / assetsi | -- | -- |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | 27.37 |
| ROA %i | -- | -- | -- | -- | 12.44 |
| ROIC %i | -- | -- | -- | -- | 27.19 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -47.47 |
| FCF / sales %i | -- | -- | -- | -- | -- |
| Current ratioi | -- | -- | 31.62 | 18.22 | 41.62 |
| Quick ratioi | -- | -- | 31.05 | 17.67 | 37.77 |
| Debt / assetsi | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- |
Quote time 2026-11-20 19:59:51 · For reference only, not investment advice and not tailored to your situation.
Hyperliquid Strategies discussion 0 comments